国产新冠灭活疫苗实物亮相服贸会,引发全场关注!或将这个时间上市

国产新冠灭活疫苗实物亮相服贸会,引发全场关注!或将这个时间上市
[标签:标题]收录于话题

在9月5日-9日于北京举办的2020年中国国际服务贸易交易会上,两家企业的国产新冠灭活疫苗实物集体亮相,引来全场关注。与此同时,“国产新冠灭活疫苗实物首次亮相服贸会”的话题也迅速冲上热搜榜。

服贸会上,展品缤纷,大咖云集,小小的疫苗却成为“主咖”。

图源:人民视觉

据南方日报记者了解,新冠肺炎疫苗的技术路径均为灭活疫苗,分别来自国药集团中国生物旗下的北京和武汉两个生物制品研究所,以及科兴控股生物技术有限公司。

Chinese people’s confidence in domestic COVID-19 vaccines has grown higher as two Chinese companies presented their candidate vaccines at this year’s China International Fair for Trade in Services (CIFTIS) in Beijing over the weekend, which demonstrates the country’s leading position in pharmaceutical research against the deadly pandemic and would also help promote domestic COVID-19 vaccines in the international market, experts said.

The adjoining booths of China National Biotec Group (CNBG) and Sinovac Biotech in the CIFTIS main exhibition hall were among the services trade fair’s top attractions since it opened on Friday. The two vaccine developers presented their candidate vaccines at the opening ceremony of the fair.

图源:人民视觉据环球时报记者了解,中国生物参展的新冠灭活疫苗目前均已进入最后的Ⅲ期临床试验阶段,正在阿联酋、巴林、秘鲁、摩洛哥、阿根廷等国家和地区紧锣密鼓地展开。入组接种5万人、样本人群现已覆盖115个国家,各方面进展均全球领先。与此同时,中国生物于北京和武汉两个生物制品研究所分别建设高等级生物安全生产设施,两个疫苗生产车间年产能合计可达3亿剂。

图源:人民视觉

CNBG, a biological producer under the state-owned China National Pharmaceutical Group Sinopharm (Sinopharm), has also launched clinical research in many countries including the United Arab Emirates, Bahrain, Argentina, Pe英亚iOS版下载ru, and Morocco, Zhang Yuntao, CNBG vice president and chief scientist told the Global Times last Friday. 英亚He said that CNBG is maintaining close communication with the World Health Organization (WHO) and joined the WHO-initiated solidarity trial for COVID-19 treatments.

The company’s international clinical trial plan has involved more than 50,000 volunteers from 115 countries, media reported.

CNBG is upgrading its manufacturing technique英亚国际apps to expand its production capacity of COVID-19 vaccines from 200 million doses per year to 300 million doses per year, Zhang told media on Friday.

国药集团中国生物营销中心副总经理罗林云介绍,如果试验顺利,疫苗将于今年年底正式上市。

视频来源:新京报我们视频

科兴公司相关负责人告诉记者,其公司研发的名为“克尔来福”的新冠肺炎灭活疫苗,也正陆续在巴西、印度尼西亚等多个国家稳步推进三期临床研究。

图源:人民视觉

据介绍,科兴公司在2020年3月底启动新型冠状病毒灭活疫苗产业化建设项目,25天完成前期施工手续,100天完成新冠疫苗生产车间及其附属设施建设,形成了年产3亿剂以上的产能。2020年8月底,这条全新的新冠疫苗生产线经专家评估和相关部门批准后,已投入使用开始批量生产。

图源:人民视觉

Sinavac has reportedly kicked off phase III clinical trials in Brazil and Indonesia and also obtained approvals from two other countries for the phase III trials.

Pearson Liu, spokesperson for the NASDAQ-listed Sinovac, told the Global Times on Friday that the company is hoping the vaccine will be licensed for use by the year’s end.

Sinovac’s designed p英亚电竞app下载roduction capacity for the vaccine is 300 million doses annually, media reported.

世卫组织:优先为这些人群接种

瑞士日内瓦当地时间9月4日,世界卫生组织总干事谭德塞在记者会上呼吁全球各国联合应对新冠疫情,称“疫苗民族主义”只会拉长疫情持续的时间。谭德塞表示:将疫苗作为全球公共资源符合每一个国家的民族利益。

WHO Director-General Tedros Adhanom Ghebreyesus reiterated at a Friday briefing that vaccine nationalism will prolong the problem, not shorten it.

Tedros said using vaccines effectively across the world is “a global public good” and it is in the “the national interest of each and every country.”

据新华社报道,谭德塞4日表示,未来新冠疫苗正式投入使用后,由于初期供应量有限,首要任务是为所有国家的特定人群接种,而不是一些国家的所有人。

谭德塞在当天的例行记者会上说,我们都希望未来几个月会有关于新冠疫苗的好消息。一旦获得安全有效的疫苗,初期供应量应该是有限的,因此必须优先考虑为关键部门从业人员和高风险人群接种,包括老年人和有基础疾病人群。这不仅在道德责任和公共卫生职责上有必要,在经济上也是如此。未来随着疫苗产量增加,所有人都能获得接种疫苗的机会。

谭德塞介绍说,目前有9种新英亚平台冠候选疫苗得到了流行病防范创新联盟(CEPI)的支持,其中7种正在开展临床试验,如果成功,将纳入COVID-19疫苗全球获取机制COVAX。此外,世卫组织还正在就4种有希望的候选疫苗展开讨论,并评估是否将其他9种目前仍处于早期研发阶段的候选疫苗纳入COVAX。

COVAX全球新冠疫苗计划由世卫组织主导,目标是2021年年底前在全球范围内提供至少20亿剂安全有效的新冠疫苗。这一计划包括联合采购和分担多种新冠疫苗风险的国际机制,无论哪种疫苗将来被证明安全有效,参与国都能够及时获得这些疫苗,不论是中低收入国家还是高收入国家。

谭德塞说,目前已有78个中高收入国家和经济体确认将加入COVAX,包括德国、日本、挪威等,且这一数字还在不断增加。谭德塞此前介绍说,已有172个国家和地区表示加入世卫组织主导的COVAX全球新冠疫苗计划。

世卫组织首席科学家苏米娅斯瓦米纳坦则表示,目前新冠疫苗仍处于早期研发阶段,还需经过多项测试。预计到2021年年中,新冠疫苗将开始进入各国。

综合来源:光明日报、环球时报、中国青年报、新华网、南方日报

————世纪君开通视频号啦————

发表评论

电子邮件地址不会被公开。 必填项已用*标注